SCHEMBL7121250

SCHEMBL7121250

CCCc1c(OC#CC2CC2)c2cc(F)ccc2[nH]c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GHSR Q92847 1/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
GSK3B P49841 1/20 0.36
MPO P05164 1/20 0.35
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
CNR1 P21554 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PARP1 P09874 1/20 0.33
APOL1 O14791 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114324 0.92 MPO (0.37) TSHRHSD17B10GHSRKDM4EALDH1A1
SCHEMBL7120967 0.87 SIRT1 (0.42) TSHRHSD17B10RAB9AKDM4EALDH1A1
SCHEMBL7122447 0.86 KEAP1 (0.34) GHSRKDM4EALDH1A1HPGDHTT
SCHEMBL7114083 0.81 KDM4E (0.36) KDM4EALDH1A1HPGDHTTKEAP1
SCHEMBL7119334 0.81 HSD17B10 (0.45) TSHRHSD17B10GHSRRAB9AKDM4E
SCHEMBL7116504 0.77 TSHR (0.42) TSHRHSD17B10GHSRRAB9AKDM4E
SCHEMBL7121392 0.71 KDM4E (0.65) TSHRHSD17B10GHSRRAB9AKDM4E
SCHEMBL7114808 0.69 PARP15 (0.43) HSD17B10GHSRRAB9AKDM4EALDH1A1
SCHEMBL7122490 0.68 HSD17B10 (0.62) TSHRHSD17B10RAB9AKDM4EALDH1A1
SCHEMBL7116752 0.68 SIRT1 (0.40) KDM4EALDH1A1HPGDMAPTGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US claimed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP claimed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO claimed
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 TSHR 4728/4885HSD17B10 1601/4885GHSR 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.